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Eosinophil arrest and recruitment to the airway in asthma are mediated, at least in part, by
integrins. Eosinophils express α4β1, α6β1, αLβ2, αMβ2, αXβ2, αDβ2, and α4β7 integrins, which
interact with counter-receptors on other cells or ligands in the extracellular matrix.Whether
a given integrin-ligand pair mediates cell adhesion and migration depends on the activation
state of the integrin. Integrins exist in an inactive bent, an intermediate-activity extended
closed, and a high-activity extended open conformation. Integrin activation states can be
monitored by conformation-specific monoclonal antibodies (mAbs). Studies in mice indicate
that both β1 and β2 integrins mediate eosinophil recruitment to the lung. In vitro stud-
ies indicate that α4β1 and αMβ2 are the principal integrins mediating eosinophil adhesion,
including to vascular cell adhesion molecule-1 and the novel αMβ2 ligand periostin. In vivo,
blood eosinophils have intermediate-activity β1 integrins, as judged by mAb N29, apparently
resulting from eosinophil binding of P-selectin on the surface of activated platelets, and
have a proportion of their β2 integrins in the intermediate conformation, as judged by mAb
KIM-127, apparently due to exposure to low concentrations of interleukin-5 (IL-5). Airway
eosinophils recovered by bronchoalveolar lavage (BAL) after segmental antigen challenge
have high-activity β1 integrins and high-activity αMβ2 that does not require IL-5. Here we
review information on how the activation states of eosinophil β1 and β2 integrins correlate
with measurements of eosinophil recruitment and pulmonary function in asthma. Blood
eosinophil N29 reactivity is associated with decreased lung function under various circum-
stances in non-severe asthma and KIM-127 with BAL eosinophil numbers, indicating that
intermediate-activity α4β1 and αMβ2 of blood eosinophils are important for eosinophil arrest
and consequently for recruitment and aspects of asthma.
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INTRODUCTION
Eosinophilic airway inflammation is frequent pattern in different
phenotypes or endotypes of asthma (Busse and Lemanske, 2001;
Scott and Wardlaw, 2006; Simpson et al., 2006; Anderson, 2008;
Haldar et al., 2008; Hogan et al., 2008; Blanchard and Rothenberg,
2009; Woodruff et al., 2009; Hastie et al., 2010; Lee et al., 2010;
Moore et al., 2010; Kita, 2011; Lotvall et al., 2011; Siroux et al., 2011;
Wang et al., 2011; Agache et al., 2012; Wenzel, 2012; Rosenberg
et al., 2013). Airway eosinophilia is associated with exacerbations
(Haldar et al., 2009; Nair et al., 2009; Busse et al., 2010; Pavord
et al., 2012; Robinson, 2013) and has been suggested to play a role
in airway remodeling (Flood-Page et al., 2003; Kay et al., 2004;
Wills-Karp and Karp, 2004; Busse et al., 2010; Robinson, 2013).
Arrest of eosinophils in vessels and their extravasation into the
airway wall and through the bronchial tissue and epithelium to the
airway lumen are mediated in part by the integrin family of cell
adhesion receptors (Banerjee et al., 2007, 2009; Rosenberg et al.,
2007; Barthel et al., 2008).
Integrins are heterodimers of α and β subunits (Hynes, 1987;
Ruoslahti, 1991). Each integrin interacts or potentially interacts
with counter-receptors on other cells or ligands deposited as
part of the extracellular matrix (ECM) (Humphries et al., 2006).
Whether a given pair of integrin and counter-receptor/ECM lig-
and participates in cell adhesion and migration depends on the
cell-surface density of the integrin, the density of the ligand, and
the activation state of the integrin (Huttenlocher et al., 1996;
Palecek et al., 1997; Askari et al., 2009). Integrins exist in three
major conformations, including an inactive or low-activity, bent
conformation; an intermediate-activity, extended, “closed” con-
formation with a partially occluded ligand-binding “head piece”;
and a high-activity, extended, “open” conformation with a more
open “head piece,” swung-out hybrid domain, and separation of
the “legs” of the two subunits (Figure 1) (Luo and Springer, 2006;
Luo et al., 2007; Evans et al., 2009; Hogg et al., 2011; Margadant
et al., 2011). The activation states of integrins can be monitored
by conformation-specific monoclonal antibodies (mAbs) (Table 1;
Figure 1) (Humphries, 2004; Byron et al., 2009). Integrins are acti-
vated through so-called “inside-out” signaling by signals triggered
through other receptors, including G-protein coupled receptors
(GPCRs) for chemokines, and mediated by cytoplasmic factors
including talin and kindlins that bind the cytoplasmic tail of inte-
grin β subunits (Evans et al., 2009; Harburger and Calderwood,
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FIGURE 1 | Models of integrin conformations with epitopes for
activation-sensitive mAbs. (A) Domains of an integrin α subunit. (B)
Domains of an integrin β subunit. (C) Conformational changes during
activation of αMβ2 that uncover epitopes for anti-β2 KIM-127 and mAb24, and
anti-αM CBRM1/5. (D) Conformational changes during activation of α4β1 that
uncover epitopes for anti-β1 N29, 8E3, HUTS-21, and 9EG7. (1) Inactive, bent
conformations; (2) intermediate-activity, extended, closed conformations; (3)
high-activity, extended, open conformations. In (C) conformation 1 of αMβ2 is
presumably KIM-127−/mAb24−/CBRM1/5−, conformation 2
KIM-127+/mAb24−/CBRM1/5−, and conformation 3
KIM-127+/mAb24+/CBRM1/5+. In (D) conformation 1 of α4β1 is presumably
N29−/8E3−/HUTS-21−/9EG7−, conformation 2 N29+/8E3+/HUTS-21−/
9EG7−, and conformation 3 N29+/8E3+/HUTS-21+/9EG7+. Green circle,
ligand-binding site in αI domain in (C) or βI domain in (D), or binding site in βI
domain for activated αI domain in (C). Green arrow, cytoplasmic proteins,
including talin and kindlins, that bind the β integrin subunit tail and mediate
activation. β-prop., β-propeller domain; EGF, integrin epidermal growth
factor-like domain; PSI, plexin-semaphorin-integrin domain. Based on (Luo and
Springer, 2006; Luo et al., 2007; Barthel et al., 2008; Evans et al., 2009; Hogg
et al., 2011).
2009; Shattil et al., 2010; Hogg et al., 2011; Margadant et al., 2011).
Engagement of integrins by ligands, in turn, can activate cyto-
plasmic signaling pathways,“outside-in”signaling (Harburger and
Calderwood, 2009; Margadant et al., 2011).
EOSINOPHIL INTEGRINS
We briefly discuss the eosinophil integrin repertoire and their
counter-receptors, ligands or potential ligands here, focusing on
recent novel information. For a more extensive overview over
eosinophil integrins and their ligands, including potential func-
tions of the integrins that are not the focus here, we refer the
reader to our previous review (Barthel et al., 2008). Eosinophils
possess a unique repertoire of seven integrins, α4β1, α6β1, αLβ2,
αMβ2, αXβ2, αDβ2, and α4β7 integrins (Barthel et al., 2008; Hogan
et al., 2008). Eosinophil integrins have the potential to mediate
adhesion and migration on vascular cell adhesion molecule-1
(VCAM-1) via α4β1, αMβ2, αXβ2, αDβ2, and α4β7; intercellular
adhesion molecule-1 (ICAM-1) via αLβ2 and αMβ2; laminin
via α6β1; fibrinogen/fibrin via αMβ2 and αXβ2; and vitronectin
via αMβ2 (Barthel et al., 2008). In our hands, purified human
blood eosinophils, in the absence of added soluble stimulus,
adhere in vitro specifically only to VCAM-1, primarily via α4β1.
Eosinophils from some subjects and eosinophils under flow con-
ditions also adhere to VCAM-1 via αMβ2 (Barthel et al., 2006a,b).
Purified airway eosinophils, recovered by bronchoalveolar lavage
(BAL) 48 h after segmental lung antigen challenge (a model of
allergic airway inflammation), or blood eosinophils stimulated
with interleukin-5 (IL-5), adhere specifically to VCAM-1 via
α4β1 and αMβ2, and to ICAM-1, fibrinogen, and vitronectin via
αMβ2 (Barthel et al., 2006b). In addition, we recently discovered
that blood eosinophils stimulated with IL-5, IL-3, or granulo-
cyte macrophage-colony stimulating factor (GM-CSF) specifically
adhere to and migrate on periostin via αMβ2 (Johansson et al.,
2013b). Periostin is an ECM protein upregulated by T helper cell
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Table 1 | Some activation-sensitive anti-integrin antibodies.
Antibody Integrin subunit Epitope location Recognized conformation(s) Reference
N29 β1 PSI domain Intermediate- and high-activity Wilkins et al. (1996), Ni et al. (1998), Mould et al.
(2005), Barthel et al. (2008), Byron et al. (2009)
8E3 β1 PSI domain Intermediate- and high-activity Coe et al. (2001), Mould et al. (2005), Barthel et al.
(2008), Byron et al. (2009)
HUTS-21 β1 Hybrid domain High-activity Luque et al. (1996), Barthel et al. (2008)
9EG7 β1 EGF-like domains High-activity Lenter et al. (1993), Bazzoni et al. (1995), Barthel
et al. (2008), Byron et al. (2009)
KIM-127 β2 2nd EGF-like domain Intermediate- and high-activity Robinson et al. (1992), Beglova et al. (2002), Byron
et al. (2009), Evans et al. (2009)
mAb24 β2 I domain High-activity Dransfield and Hogg (1989), Leitinger and Hogg
(2000), Lu et al. (2001), Byron et al. (2009), Evans
et al. (2009)
CBRM1/5 αM I domain High-activity Oxvig et al. (1999), Byron et al. (2009)
EGF, epidermal growth factor; PSI, plexin-semaphorin-integrin.
type 2 (Th2) cytokines in bronchial epithelial cells and lung fibrob-
lasts and is deposited in patients with asthma and atopic dermatitis,
as well as in animal models of asthma and allergic skin inflamma-
tion (Yuyama et al., 2002; Takayama et al., 2006; Hayashi et al.,
2007; Woodruff et al., 2007; Masuoka et al., 2012). Mice lack-
ing periostin respond to lung antigen challenge with significantly
decreased number of eosinophils in the lung and have reduced
allergic skin inflammation (Blanchard et al., 2008; Bentley et al.,
2012; Masuoka et al., 2012), thus implicating periostin as a ligand
in eosinophil recruitment and retention in allergy and asthma.
Further, studies of β2-deficient and conditionallyα4-deficient mice
indicate that both β2 and α4, presumably principally α4β1, inte-
grins mediate trafficking of eosinophils to the lung in models of
allergen-induced acute and chronic asthma (Banerjee et al., 2007,
2009).
Taken together, these studies in mice and men indicate thatα4β1
and αMβ2 are the major eosinophil integrins mediating cell adhe-
sion, with α4β1 largely responsible for arrest of blood eosinophils
on VCAM-1 in vessels of the asthmatic lung, with a more minor
contribution by αMβ2; whereas activated αMβ2, by interacting
with periostin and possibly other ligands, is involved in subse-
quent eosinophil recruitment to and persistence in the ECM of
the bronchi in asthma.
ACTIVATION STATES OF INTEGRINS ON BLOOD AND
AIRWAY EOSINOPHILS
As purification of eosinophils leads to increased partial activation
of β1 integrins, assessed by mAb N29 (Johansson and Mosher,
2011); we monitor activation states of integrins on blood and air-
way eosinophils by processing unfractionated blood or BAL cells
for flow cytometry and analyzing eosinophils, which are gated to
exclude other cells, including neutrophils, monocytes, lympho-
cytes, and NK cells, based on CD14 and CD16 staining and scatter
(Johansson et al., 2006, 2008, 2012, 2013a; Johansson and Mosher,
2011).
On the average, eosinophils in blood express the N29 and 8E3
epitopes to some degree but have no or very low expression of the
HUTS-21 and 9EG7 epitopes, indicating that their β1 integrins,
including α4β1, are in the intermediate-, but not high-activity,
conformation (Table 1; Figure 1) (Johansson et al., 2006, 2008,
2012, 2013a; Johansson and Mosher, 2011). However, N29 and 8E3
reactivities are variable among subjects, ranging from some sub-
jects with essentially no N29 signal and thus inactive β1 integrins
to some with low but detectable N29 signal (i.e., a fraction of β1
integrin molecules on each cell having the intermediate-activity
conformation) to some with high N29 signal (i.e., presumably
most molecules having the intermediate-activity conformation)
(Johansson et al., 2008, 2012; Johansson and Mosher, 2011). As a
group, subjects with asthma or subjects with non-severe asthma,
but not subjects with severe asthma, have a higher N29 signal than
normal donors (Johansson et al., 2012). In subjects with non-
severe allergic asthma who have a dual response phenotype (i.e.,
they have a fall in forced expiratory volume in 1 s (FEV1) of≥15%
during the late-phase 3–8 h after whole-lung antigen challenge,
in addition to the common initial early-phase fall within 15–
30 min), N29 reactivity was increased 48 h after segmental lung
antigen challenge (Johansson et al., 2008). After whole-lung anti-
gen challenge itself, which is a more major insult and a model
of asthma exacerbation (Gauvreau and Evans, 2007), N29 reac-
tivity of circulating eosinophils decreases at 8 h and recovers at
48 h, indicating that cells with the highest proportion of acti-
vated α4β1 are the ones that extravasate. We have suggested that
a similar phenomenon, i.e., that the eosinophils with the most
activated α4β1 are efficiently removed, occurs continuously in
severe asthma, compatible with the data that the N29 signal on
circulating cells in severe asthma is not significantly higher than
in normal donors (Johansson et al., 2012). Efficient removal in
severe asthma may be due to greater lung endothelial VCAM-1
expression, as has been observed in bronchial biopsies of sub-
jects with severe compared to non-severe asthma (Ramos-Barbon
et al., 2010). Taken together, this information indicates that a
proportion, variable among subjects, of the α4β1 molecules on
blood eosinophils are in an intermediate conformation. This pro-
portion is higher in asthma than in healthy donors, and can
increase, e.g., upon segmental antigen challenge, but can also
decrease when or if the most activated cells extravasate, such as
after whole-lung challenge or presumably continuously in severe
asthma.
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Purified blood eosinophils are positive for N29 but not HUTS-
21 and 9EG7, and adhere “constitutively” to VCAM-1 in vitro in
an α4β1-dependent manner (Barthel et al., 2006a,b); compatible
with a situation in which all or most of their α4β1 molecules are
in the intermediate conformation. However, purified cells are not
a completely accurate reflection of eosinophils in vivo, since, as
indicated above, the N29 signal increases upon cell purification
(Johansson and Mosher, 2011). Thus, as eosinophils from differ-
ent subjects in vivo have variable N29 reactivity, it is reasonable
to assume that the capacity of eosinophils to arrest on VCAM-1
in vivo also varies among subjects.
Regarding β2 integrins, eosinophils in blood (from subjects
with non-severe asthma) have a low but detectable KIM-127
signal but very low reactivity with mAb24 and CBRM1/5, indi-
cating that a fraction of their β2 integrins, including αMβ2, is in
the intermediate- (but not high-) activity conformation (Johans-
son et al., 2008, 2013a). In consistency with this, purified blood
eosinophils do not react with CBRM1/5 and do not adhere
in vitro to the αMβ2 ligands ICAM-1, fibrinogen, vitronectin, and
periostin, unless IL-5 is added to stimulate the cells (Barthel et al.,
2006b; Johansson et al., 2013b). However, since, as mentioned,
αMβ2, in addition to α4β1, is involved in adhesion of purified
blood eosinophils from some subjects to VCAM-1 and mediates
arrest to VCAM-1 under flow (Barthel et al., 2006a), a proportion
of αMβ2 on blood eosinophils in the intermediate conformation
is likely sufficient for αMβ2 to participate, together with α4β1, in
arrest to VCAM-1.
Eosinophils in BAL obtained after segmental antigen chal-
lenge have β1 integrins in the high-activity conformation, judged
by their significantly increased reactivity with HUTS-21 and
9EG7 compared to blood eosinophils (Johansson et al., 2013a).
αMβ2 on such BAL eosinophils also is in a high-activity con-
formation, as assessed by the higher reactivity with mAb24 and
CBRM1/5 than on blood eosinophils (Johansson et al., 2008,
2013a) and very high reactivity with KIM-127 (Johansson et al.,
2013a). These flow cytometry data on eosinophils in BAL agree
with the fact that purified airway eosinophils adhere to VCAM-1
to a higher degree than blood eosinophils in a process involv-
ing both α4β1 and αMβ2, and adhere to ICAM-1, fibrinogen,
and vitronectin in a αMβ2-dependent manner (Barthel et al.,
2006b).
ACTIVATING STIMULI
Addition of soluble P-selectin to whole blood in vitro increases the
N29 signal of blood eosinophils and their adhesion to VCAM-1
(Johansson and Mosher, 2011), thus enhancing the activation of
α4β1. Added P-selectin does not enhance the N29 signal or adhe-
sion of purified blood eosinophils to VCAM-1, in consistency with
the fact that N29 is increased and thus α4β1 is activated during
cell purification (Johansson and Mosher, 2011). We suspect that
in the process of purification, contaminating platelets are acti-
vated, externalizing P-selectin and in turn activating eosinophils.
In whole blood samples, eosinophil reactivity with N29 or 8E3 cor-
relates with the amount of P-selectin associated with the eosinophil
surface in non-severe asthma (Table 2) (Johansson and Mosher,
2011), and N29 does so also in a population of subjects with
asthma of varying severity (Table 2) (Johansson et al., 2012).
Further, eosinophil N29 correlates with platelet-surface P-selectin
expression (Johansson et al., 2012). These correlations support a
scenario in which P-selectin present on the surface of activated
platelets is the in vivo stimulus that by binding to eosinophils,
presumably via P-selectin glycoprotein ligand-1 (PSGL-1), the
eosinophil counter-receptor for P-selectin (Symon et al., 1996),
triggers an intracellular signaling pathway that results in conver-
sion of inactive to intermediate-activity α4β1 and the stimulation
of arrest on VCAM-1. As with the N29 signal, after whole-lung
antigen challenge, eosinophil-bound P-selectin and eosinophil
PSGL-1 decreased at 8 h and recovered at 48 h (Johansson et al.,
2012), indicating that the cells with the highest PSGL-1 level and
P-selectin binding, as well as highest degree of α4β1 activation,
extravasate. This situation is compatible with studies on platelet-
depleted mice and mice restored with activated platelets, which
showed that eosinophil recruitment after lung antigen challenge
required activated platelets in a P-selectin-dependent manner
(Pitchford et al., 2005).
As alluded to above, IL-5 at concentrations≥1 ng/ml (∼40 pM)
induces blood eosinophil reactivity with CBRM1/5 and mAb24,
and adhesion to αMβ2 ligands in vitro (Zhu et al., 1999; Barthel
et al., 2006a,b; Johansson and Mosher, 2011; Johansson et al.,
2013b). In vivo, the KIM-127 signal of blood eosinophils was
decreased in subjects with non-severe asthma after administra-
tion of anti-IL-5 mepolizumab (Table 2) (Johansson et al., 2013a),
indicating that the intermediate conformation of β2 integrins on
Table 2 | Evidence for eosinophil integrin activating stimuli in vivo.
Location Integrin Activation state Activating stimuli Evidence and reference
Blood β1 integrins Intermediate P-selectin Eosinophil-bound P-selectin correlates with N29 and 8E3 reac-
tivities (Johansson and Mosher, 2011; Johansson et al., 2012),
platelet-surface P-selectin correlates with N29 reactivity (Johans-
son et al., 2012)
β2 integrins Intermediate IL-5 (low concentrations) Anti-IL-5 decreases KIM-127 reactivity (Johansson et al., 2013a)
Airway β1 integrins High Unknown Johansson et al. (2013a)
β2 integrins High Unknown
(IL-5 may play a role
but not required)
BAL fluid IL-5 concentration correlates with mAb24 reactivity
(Johansson et al., 2008), but anti-IL-5 does not decrease mAb24
and CBRM1/5 reactivities (Johansson et al., 2013a)
BAL, bronchoalveolar lavage; IL-5, interleukin-5.
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blood eosinophils is the result of exposure to IL-5 in the bone
marrow and/or circulation. This IL-5 concentration is presumably
low, since it does not result in significant expression of the mAb24
and CBRM1/5 epitopes in fully activated αMβ2; and the IL-5 con-
centration in the blood of subjects with asthma is only 1–10 pg/ml
(0.04–0.4 pM) (Mastalerz et al., 2001; Joseph et al., 2004; Johnsson
et al., 2011). Thus, KIM-127 reactivity may be a read-out of tonic
in vivo IL-5 activity and may predict responsiveness to anti-IL-5.
As for airway eosinophils, we do not know what factor is
responsible for their high-activity β1 integrin state. We speculate
that it may be the result of the eosinophils having undergone
arrest, transendothelial migration, and encounters with adhesive
ligands. Current thinking in the leukocyte integrin field includes
the possibility that outside-in signaling following ligand-binding
by integrin in the intermediate conformation brings about the
final stage of activation to the high-activity conformation (Evans
et al., 2009; Hogg et al., 2011). Thus, for eosinophil α4β1, interac-
tion with VCAM-1 during arrest and transmigration may lead to
higher activation, as detected on airway eosinophils.
In our first segmental antigen challenge study, mAb24 reactivity
of BAL eosinophils correlated with IL-5 concentration in BAL fluid
(Table 2) (Johansson et al., 2008), indicating that IL-5 can be an
in vivo stimulus for the high-activation state of airway eosinophil
β2 integrins. The concentration of IL-5 in airway lining fluid in vivo
is 0.1–100 ng/ml (Teran et al., 1999; Kelly et al., 2003; Johansson
et al., 2008), based on the estimated 100-fold dilution during the
recovery of BAL (Rennard et al., 1986; Johansson et al., 2008).
However, in contrast to blood eosinophil reactivity with KIM-127;
BAL eosinophil reactivities with KIM-127, mAb24, and CBRM1/5
did not decrease after anti-IL-5 administration (Table 2) (Johans-
son et al., 2013a). Thus, the high-activity αMβ2 state of airway
eosinophils does not appear to require IL-5. Presumably, IL-3
and/or GM-CSF, which can induce adhesion to an αMβ2 ligand
in vitro (Johansson et al., 2013b) and which are estimated to be
present at up to 10 ng/ml in airway lining fluid (Woolley et al.,
1995; Evans et al., 1996; Jarjour et al., 1997; Johansson et al., 2008),
may, possibly together with other factors, be responsible for the
highly activated αMβ2 on airway eosinophils in vivo.
In conclusion,P-selectin or IL-5 appears responsible for the par-
tial activation of α4β1 or αMβ2, respectively, on blood eosinophils.
These data demonstrate that different integrins on eosinophils are
activated by distinct stimuli and presumably by distinct signaling
pathways, which is in accordance with a recent statement that “it
is clear that mechanisms of activation are not generic for all inte-
grins” (Margadant et al., 2011). In contrast, it is uncertain which
factor or combinations of factors bring about the high-activation
state of α4β1 and αMβ2 on airway eosinophils. IL-3, GM-CSF,
and/or other agents, possibly in synergy, may be responsible for the
high-activity αMβ2. IL-5 may play a minor, but dispensable, role.
Interactions with counter-receptors or ligands during arrest, and
transendothelial and continued migration may be responsible for
high-activity α4β1 and may also contribute to high-activity αMβ2.
CORRELATIONS WITH EOSINOPHIL RECRUITMENT AND
ASPECTS OF ASTHMA
Although it was known that purified blood eosinophils adhere
“constitutively” to VCAM-1 in vitro (Walsh et al., 1991; Weller
et al., 1991; Schleimer et al., 1992; Johansson et al., 2004; Barthel
et al., 2006a,b), the possibility existed that the activation state of
α4β1 in vivo would be variable and a determinant of eosinophil
arrest on activated endothelium and consequently recruitment
to the airway. We first tested this possibility in a double-blind
placebo-controlled, two-period crossover inhaled corticosteroid
(ICS) withdrawal study in subjects with non-severe asthma. N29
reactivity of blood eosinophils was found to correlate inversely
with forced expiratory volume in 1 s (FEV1, as percentage of base-
line) after ICS withdrawal or across all visits during the whole study
(Table 3) (Johansson et al., 2006). Receiver-operator characteristic
(ROC) curve analysis demonstrated that the N29 signal predicted
decrease in FEV1 (Table 3) (Johansson et al., 2006). N29 corre-
lated better with FEV1 and performed better in ROC analysis than
did the established asthma biomarkers sputum eosinophil per-
centage and fraction of exhaled nitric oxide (FENO) (Johansson
et al., 2006). Further, N29 correlated with FENO, believed to reflect
airway inflammation, after ICS withdrawal (Table 3) (Johansson
et al., 2006). These findings indicated that greater β1 activation
(i.e., higher proportion of β1 integrins in the intermediate confor-
mation vs. in the inactive conformation) on circulating eosinophils
is associated with a higher degree of airway inflammation and
decreased pulmonary function in non-severe asthma, presumably
because subjects with a more activated α4β1 would have a higher
degree of eosinophil arrest and recruitment to the airway.
To test the hypothesis that blood eosinophil β1 activation is
clinically relevant in asthma in another model, we used segmental
lung antigen challenge of subjects with non-severe allergic asthma.
Blood eosinophil N29 reactivity 48 h after segmental challenge cor-
related with the late-phase fall in FEV1 3–8 h after the whole-lung
antigen challenge performed during screening (Table 3) (Johans-
son et al., 2008). N29 signal of airway eosinophils obtained 48 h
after segmental challenge correlated with eosinophil percentage in
BAL and was higher in dual than in single responders (Table 3)
(Johansson et al., 2008). These results confirmed that degree of
β1 activation on blood eosinophils is associated with pulmonary
function in non-severe asthma and also showed that the β1 activa-
tion that occurs on airway eosinophils is associated with eosinophil
recruitment. Unfortunately, blood during the screening whole-
lung antigen challenge part of this study was not analyzed by
flow cytometry. It would be interesting to investigate more directly
correlations between integrin activation during whole-lung anti-
gen challenge and measures of eosinophil recruitment, airway
inflammation, and the late-phase response, by comparing flow
cytometry data and clinical parameters at different time points
after whole-lung challenge.
The ICS withdrawal and antigen challenge studies were on
subjects with non-severe asthma who were young adults (mean
21 years old, only one of 27 subjects older than 30) (Johansson
et al., 2008). To extend the study on the relationships between β1
integrin activation on blood eosinophils and pulmonary function
to subjects with disease of varying severity and a greater age range,
we performed an observational study in a population comprising
both non-severe and severe asthma subjects with a higher mean
age (34 for those with severe and 29 for those with non-severe
asthma). As there was no baseline in this observational study,
we examined correlations with FEV1 corrected for forced vital
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Table 3 | Correlations between eosinophil integrin activation states and eosinophil recruitment or aspects of asthma.
Location Integrin: activation state (mAb) Correlation Reference
Blood β1 Integrins: intermediate (N29) Inverse with FEV1 (% of baseline) after or during ICS with-
drawal in non-severe asthma, predicts decrease in FEV1 in
receiver-operator characteristic (ROC) curve analysis
Johansson et al. (2006)
FENO after ICS withdrawal in non-severe asthma Johansson et al. (2006)
Inverse with FEV1/FVC in younger subjects with non-severe
asthma
Johansson et al. (2012)
Inverse with FEV1/FVC in cluster 1 (mild atopic asthma) Johansson et al. (2011)
(48 h after segmental antigen challenge) Response phenotype (increased vs. 0 h in dual, not single,
responders)
Johansson et al. (2008)
(48 h after segmental antigen challenge) Late-phase fall in% FEV1 after whole-lung antigen challenge Johansson et al. (2008)
β2 Integrins: intermediate (KIM-127) (before but not
after anti-IL-5)
% BAL eosinophils Johansson et al. (2013a)
Airway β1 Integrins: intermediate-high (N29) % BAL eosinophils Johansson et al. (2008)
Response phenotype (higher in dual than in single respon-
ders)
Johansson et al. (2008)
β2 Integrins: high (mAb24) % BAL eosinophils Johansson et al. (2008)
Late-phase fall in% FEV1 after whole-lung antigen challenge Johansson et al. (2008)
BAL, bronchoalveolar lavage; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid.
capacity (FVC). The correlation between N29 reactivity of blood
eosinophils with FEV1/FVC did not reach significance in the whole
asthma study population (Johansson et al., 2012). However, when
subjects were stratified by severity and age, N29 correlated sig-
nificantly with FEV1/FVC in those with non-severe asthma under
30 years of age (Table 3) (Johansson et al., 2012). The subjects in
this study belonged to a population that had been classified using
unsupervised hierarchical cluster analysis, resulting in five asthma
phenotype groups (Moore et al., 2010). N29 correlated best and
significantly with FEV1/FVC in cluster 1 (Johansson et al., 2011),
which consists of subjects with mild atopic asthma (Moore et al.,
2010).
Taking ICS withdrawal, antigen challenge, and the severe
asthma studies together, it appears that greater β1 integrin activa-
tion on blood eosinophils is associated with decreased pulmonary
function in subjects with non-severe asthma who are relatively
young, but that this association breaks down in severe asthma or
in older subjects. A possible explanation for the lack of associ-
ation in severe asthma is high degree of ongoing extravasation
of eosinophils with the most activated α4β1, as discussed above.
An additional possible explanation is that a proportion of sub-
jects with severe asthma do not have a predominantly eosinophilic
airway inflammatory phenotype but rather a mixed eosinophilic-
neutrophilic or a neutrophilic phenotype (Hastie et al., 2010;
Wenzel, 2012), which may contribute to the weakening of the
association between eosinophil activation and lung function. Fur-
ther, it is unclear why the association does not hold up in older
subjects. Perhaps pulmonary function becomes less associated
with eosinophil activation and recruitment as the disease evolves
with time and increased age. Such a situation may be related
to the observation that neutrophilic inflammation in asthma is
more frequent in older adults (Wang et al., 2011; Agache et al.,
2012).
Regardingβ2 integrins, the first antigen challenge study demon-
strated that reactivity of BAL eosinophil mAb24 reactivity, like
their N29 reactivity, correlated with percentage of eosinophils in
BAL (Table 3) (Johansson et al., 2008). Further, the mAb24 signal
of BAL eosinophils correlated with the magnitude of the late-phase
response after whole-lung antigen challenge (Table 3) (Johansson
et al., 2008). In the anti-IL-5 study, blood eosinophil reactivity
with KIM-127 at the time of segmental challenge (before but not
after anti-IL-5 administration) correlated with BAL eosinophil
percentage 48 h later (Table 3) (Johansson et al., 2013a). Unfor-
tunately, KIM-127 was not assayed in the earlier studies, so the
repeatability of this observation is not known. However, these
data indicate that the degree of (intermediate) β2 integrin acti-
vation on blood eosinophils and degree of high β2 activation
achieved on airway eosinophils are also associated with eosinophil
recruitment. These correlations offer support for the view that
activation of β2 integrins, presumably αMβ2, complements activa-
tion of α4β1, in mediating eosinophil arrest and movement to the
airway.
CONCLUSIONS AND PERSPECTIVES
We review information on the activation state of integrins on blood
and airway eosinophils, the likely in vivo activators of eosinophil
integrins, and correlations between eosinophil integrin activation
and measurements of eosinophil recruitment, airway inflamma-
tion, and pulmonary function in asthma. We concentrate on
studies in humans and include results of studies done on mice.
The information indicates that a proportion of α4β1 integrin
on circulating blood eosinophils is in the intermediate-activity
conformation as a result of stimulation of eosinophils by P-
selectin present on the surface of activated platelets binding to
eosinophil PSGL-1. The proportion is variable among individu-
als, and thus α4β1 activation, by conferring variable capacity to
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arrest on VCAM-1 on activated endothelium in inflamed lung,
seems to be a biomarker of disease activity in younger individuals
with mild asthma. A proportion of αMβ2 on blood eosinophils is
also in the intermediate-activity conformation, presumably as a
result of exposure to IL-5. Partially activated αMβ2 likely assists in
eosinophil arrest on and extravasation from inflamed vessels, and
dampening of αMβ2 activation may contribute to the therapeutic
efficacy of anti-IL-5.
The classical multistep paradigm for extravasation of leuko-
cytes (Springer, 1994), which has been applied to eosinophils
(Rosenberg et al., 2007), depicts circulating leukocytes as hav-
ing inactive integrins that become activated when rolling cells are
exposed to chemokines associated with the surface of activated
endothelium. The paradigm needs to be modified to include in vivo
“pre-activation” or “priming” (Koenderman et al., 1996) mediated
by P-selectin and IL-5 causing eosinophils to display integrins in
partially activated conformations and leading to more efficient
arrest. The modified paradigm is in accord with the conclusion that
“increasing evidence suggests that subsets of circulating leukocytes
express a fraction of their integrins in pre-formed intermediate-
affinity states” that arrest or slow down rolling leukocytes (Alon
and Dustin, 2007).
Airway eosinophils obtained by BAL 48 h after segmental anti-
gen challenge have α4β1 and αMβ2 in high-activity conformations,
likely as a result of encounters with multiple factors in inflamed
lung including, in the case of high-activity αMβ2, exposure to
IL-3, GM-CSF, and other soluble agents, and/or interaction with
ligands such as VCAM-1 (for both integrins) and periostin (for
αMβ2). It is difficult to say much more without knowing the his-
tories of the sampled cells as the cells responded to the challenge.
Interestingly, degree of activation of both β1 and β2 integrins on
airway eosinophils correlates with number of eosinophils found
in BAL.
Observations on human blood eosinophils and genetically
manipulated mice indicate that partially activated α4β1 and αMβ2
on blood eosinophils cooperate in eosinophil arrest in vessels of
inflamed bronchi and movement of eosinophils into lung tissue.
α4β1 may dominate in arrest on VCAM-1, and αMβ2 may dom-
inate at the later stage by mediating extravasation and migration
in the ECM. It should be stressed that some of the observations
in humans are correlational in nature and have not yet been
replicated by others, and a number of predictions based on the
observations have not been tested. For instance, identification of
the vascular beds in which partial eosinophil integrin activation
takes place will firm up the observations. These need not to be
the beds into which eosinophils ultimately extravasate. We have
suggested that eosinophils may encounter activated platelets and
P-selectin (Johansson and Mosher, 2011; Johansson et al., 2012)
in the pulmonary circulation, which is sampled many times per
hour by all blood cells, and thus the eosinophils are primed to
extravasate when coursing through the systemic circulation of
the inflamed bronchus, which would happen much less often
(Johansson et al., 2008). It is not known whether the diminu-
tion of β2 integrin activation by anti-IL-5 is due to neutralization
of IL-5 present in low concentration in the general circulation
or at higher concentrations in certain vascular beds. Longitudi-
nal studies are needed to relate changes in integrin activation to
the natural history of asthma and thus supplement correlations
done on values obtained at a single time point. Such studies may
give insight into why β1 integrin activation on blood eosinophils
correlates with pulmonary function in younger adults with non-
severe asthma but not in patients with severe disease or older
patients. Murine experiments are needed to assess the arrest and
extravasation of eosinophils in intact blood vessels imaged in
real time and relate eosinophil behavior to integrin activation
state. Similar experiments have provided important information
about the behavior of platelets and neutrophils in injured or
inflamed vessels. Finally, more needs to be known about roles of
eosinophil integrins in modulating the movement and behavior
of eosinophils in lung tissues. Such studies may reveal important
roles for the five eosinophil integrins that are largely ignored in
this review.
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